Caption Management, LLC Vir Biotechnology, Inc. Call Options Transaction History

Caption Management, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.26 - $10.7 $130,680 - $192,600	18,000 New	18,000 $134,000
Q1 2024 May 15, 2024	SELL	$8.6 - $11.9 $645,000 - $892,500	-75,000 Reduced 76.92%	22,500 $227,000
Q4 2023 Feb 14, 2024	BUY	$7.76 - $10.29 $756,600 - $1 Million	97,500 New	97,500 $980,000
Q1 2023 May 15, 2023	BUY	$22.26 - $30.85 $770,196 - $1.07 Million	34,600 New	34,600 $805,000
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $547,800 - $933,000	30,000 Added 100.0%	60,000 $1.16 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $572,400 - $801,000	30,000 New	30,000 $764,000
Q1 2022 May 13, 2022	SELL	$21.19 - $40.01 $279,708 - $528,132	-13,200 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$30.97 - $54.03 $628,691 - $1.1 Million	-20,300 Reduced 60.6%	13,200 $551,000
Q3 2021 Nov 12, 2021	SELL	$34.9 - $54.54 $1.48 Million - $2.32 Million	-42,500 Reduced 55.92%	33,500 $1.46 Million
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $968,750 - $1.28 Million	-25,000 Reduced 24.75%	76,000 $3.59 Million
Q1 2021 May 17, 2021	BUY	$26.34 - $83.07 $2.66 Million - $8.39 Million	101,000 New	101,000 $5.18 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $979M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.